⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
XNCR News
Xencor, Inc.
Form 8-K
sec.gov
XNCR
Xencor Announces Change to Ultomiris® Royalty Revenue Forecast
businesswire.com
XNCR
Form 8-K
sec.gov
XNCR
Xencor Reports Fourth Quarter and Full Year 2025 Financial Results
businesswire.com
XNCR
Xenocor Announces FDA Clearance of Saberscope®, the First Single-Use 5mm Articulating Laparoscope for Enhanced Surgical Visualization
prnewswire.com
XNCR
Xencor to Participate at Upcoming Investor Conferences
businesswire.com
XNCR
Primmune Therapeutics Appoints Chief Medical Officer and Executive Board Chair; Establishes Melanoma Clinical Study Advisory Board
globenewswire.com
ALGN
AZN
EXEL
VRTX
XNCR
Xencor Highlights Corporate Priorities and 2026 Pipeline Milestones
businesswire.com
XNCR
Incyte Japan annonce l’autorisation de Minjuvi ® (tafasitamab) en association avec le rituximab et le lénalidomide pour le traitement du lymphome folliculaire récidivant ou réfractaire
businesswire.com
INCY
XNCR
Incyte Japan Announces Approval of Minjuvi ® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma
businesswire.com
INCY
XNCR